Novavax, Inc. (Nasdaq:
NVAX)
announced today the publication of an article that reported new safety,
immunogenicity and cross-reactivity results from a Phase I/IIa clinical study
of the company's H5N1 influenza virus-like particle vaccine candidate
that was conducted in 2008.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
